A clinical study conducted by Dr. Lawrence A. Lavery, DPM, MPH, during his term as an associate professor in the department of orthopedic surgery and rehabilitation at Loyola University Medical Center in Chicago, Illinois, evaluated subjects with a history of diabetes and vascular impairment. According to Dr. Lavery, the findings of this study were "compelling and significant".

The Testing Demonstrated:

• 8 - 12% increase in blood oxygen levels were recorded in subjects wearing the Holofiber products.
• Statistically significant increase in transcutaneous oxygen — or the oxygen delivery to the skin — in hands and feet, on subjects wearing Holofiber gloves and socks, compared to those wearing comparable non-Holofiber gloves and socks.
• Early results indicate findings that are likely to have a significant impact on the medical, consumer performancewear, and active sportswear markets.

Wellman, Inc. and Holofiber Enterprises, Inc. formed a joint venture company, Hologenix LLC, to manufacture and market Holofiber products. Wellman, a leading manufacturer of synthetic fibers and Holofiber Enterprises, a company engaged in leading edge research and development, have been actively developing this product and continue to substantiate results through scientific testing.

A wide array of yarns containing Holofiber are currently available in blends with Wellman’s family of performance fibers: Sensura®, ComFortrel Plus®, ComFortrel XP®, and Spunnaire®.

• Visit the Wellman web site and the Wellman Hosiery site
• Visit the Holofiber web site
• For Marketing and Sales contact Jim Ciccone by e-mail

HologeniX LLC.
Holofiber™ is a trademark of Holofiber Enterprises.


WELLMAN, INC.
THE FIBER DIVISION

©2003 Wellman, Inc.